

DUOBRII (halobetasol/tazarotene, topical lotion)

Diagnosis Considered for Coverage: <ul style="list-style-type: none">• Plaque Psoriasis (PsO)	
Coverage Criteria: <p>For diagnosis above:</p> <ul style="list-style-type: none">• Inadequate response with either one very high potency topical corticosteroid or topical tazarotene (Tazorac), or contraindication to both very high potency topical corticosteroid and topical tazarotene (Tazorac). <p>Table: Preferred Very High Potency Topical Corticosteroids</p> <table><tr><td><ul style="list-style-type: none">• augmented betamethasone dipropionate 0.05% gel, ointment, lotion (Diprolene)• clobetasol 0.05% cream, ointment, solution, gel, cream emollient (Temovate)• clobetasol 0.05% lotion, shampoo (Clobex)• clobetasol 0.05% foam, emollient foam (Olux, Olux-E)• halobetasol 0.05% cream, ointment (Ultravate)</td></tr></table>	<ul style="list-style-type: none">• augmented betamethasone dipropionate 0.05% gel, ointment, lotion (Diprolene)• clobetasol 0.05% cream, ointment, solution, gel, cream emollient (Temovate)• clobetasol 0.05% lotion, shampoo (Clobex)• clobetasol 0.05% foam, emollient foam (Olux, Olux-E)• halobetasol 0.05% cream, ointment (Ultravate)
<ul style="list-style-type: none">• augmented betamethasone dipropionate 0.05% gel, ointment, lotion (Diprolene)• clobetasol 0.05% cream, ointment, solution, gel, cream emollient (Temovate)• clobetasol 0.05% lotion, shampoo (Clobex)• clobetasol 0.05% foam, emollient foam (Olux, Olux-E)• halobetasol 0.05% cream, ointment (Ultravate)	
Coverage Duration: one year	

Effective Date: 1/31/2024